Cover Image
市場調查報告書

Innate Pharma SA:產品平台分析

Innate Pharma SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 257883
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
Innate Pharma SA:產品平台分析 Innate Pharma SA - Product Pipeline Review - 2015
出版日期: 2015年07月22日 內容資訊: 英文 37 Pages
簡介

本報告提供Innate Pharma SA的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Innate Pharma SA的基本資料

  • Innate Pharma SA概要
  • 主要資訊
  • 企業資料

Innate Pharma SA:R&D概要

  • 主要的治療範圍

Innate Pharma SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Innate Pharma SA:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Innate Pharma SA:藥物簡介

  • IPH-2201
  • IPH-33
  • IPH-4102
  • IPH-43
  • Monoclonal Antibody for Cancer and Inflammation
  • Monoclonal Antibody 1 for Cancer
  • Monoclonal Antibody 2 for Cancer
  • Monoclonal Antibody to Inhibit NKp46 for Cancer and Inflammation

Innate Pharma SA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Innate Pharma SA:最近的開發平台趨勢

Innate Pharma SA:暫停中的計劃

Innate Pharma SA:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • Autologous Gamma Delta T Lymphocytes
    • IPH-1101
    • IPH-1201
    • IPH-2101
    • IPH-3102
    • IPH-3201
    • IPH-4101
    • IPH-4201

Innate Pharma SA:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07280CDB

Summary

Global Markets Direct's, 'Innate Pharma SA - Product Pipeline Review - 2015', provides an overview of the Innate Pharma SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Innate Pharma SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Innate Pharma SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Innate Pharma SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Innate Pharma SA's pipeline products

Reasons to buy

  • Evaluate Innate Pharma SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Innate Pharma SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Innate Pharma SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Innate Pharma SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Innate Pharma SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Innate Pharma SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Innate Pharma SA Snapshot
    • Innate Pharma SA Overview
    • Key Information
    • Key Facts
  • Innate Pharma SA - Research and Development Overview
    • Key Therapeutic Areas
  • Innate Pharma SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Innate Pharma SA - Pipeline Products Glance
    • Innate Pharma SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Innate Pharma SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Innate Pharma SA - Drug Profiles
    • IPH-2201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPH-33
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPH-4102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPH-43
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Cancer and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 1 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 2 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit NKp46 for Cancer and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Innate Pharma SA - Pipeline Analysis
    • Innate Pharma SA - Pipeline Products by Target
    • Innate Pharma SA - Pipeline Products by Route of Administration
    • Innate Pharma SA - Pipeline Products by Molecule Type
    • Innate Pharma SA - Pipeline Products by Mechanism of Action
  • Innate Pharma SA - Recent Pipeline Updates
  • Innate Pharma SA - Dormant Projects
  • Innate Pharma SA - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Autologous Gamma Delta T Lymphocytes
      • IPH-1101
      • IPH-1201
      • IPH-2101
      • IPH-3102
      • IPH-3201
      • IPH-4101
      • IPH-4201
  • Innate Pharma SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Innate Pharma SA, Key Information
  • Innate Pharma SA, Key Facts
  • Innate Pharma SA - Pipeline by Indication, 2015
  • Innate Pharma SA - Pipeline by Stage of Development, 2015
  • Innate Pharma SA - Monotherapy Products in Pipeline, 2015
  • Innate Pharma SA - Out-Licensed Products in Pipeline, 2015
  • Innate Pharma SA - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Innate Pharma SA - Phase II, 2015
  • Innate Pharma SA - Phase I, 2015
  • Innate Pharma SA - Preclinical, 2015
  • Innate Pharma SA - Discovery, 2015
  • Innate Pharma SA - Pipeline by Target, 2015
  • Innate Pharma SA - Pipeline by Route of Administration, 2015
  • Innate Pharma SA - Pipeline by Molecule Type, 2015
  • Innate Pharma SA - Pipeline Products by Mechanism of Action, 2015
  • Innate Pharma SA - Recent Pipeline Updates, 2015
  • Innate Pharma SA - Dormant Developmental Projects,2015
  • Innate Pharma SA - Discontinued Pipeline Products, 2015
  • Innate Pharma SA, Subsidiaries

List of Figures

  • Innate Pharma SA - Pipeline by Top 10 Indication, 2015
  • Innate Pharma SA - Pipeline by Stage of Development, 2015
  • Innate Pharma SA - Monotherapy Products in Pipeline, 2015
  • Innate Pharma SA - Out-Licensed Products in Pipeline, 2015
  • Innate Pharma SA - Pipeline by Top 10 Target, 2015
  • Innate Pharma SA - Pipeline by Top 10 Route of Administration, 2015
  • Innate Pharma SA - Pipeline by Top 10 Molecule Type, 2015
  • Innate Pharma SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top